Evaluating Immunogenicity risk of Complex peptide products

Narasimha Rao (Dr Reddy’s Laboratories, India)
“At Dr. Reddy’s Laboratories, we have had the privilege of collaborating closely with ProImmune for immunogenicity risk assessment services. Their team demonstrates best-in-class expertise in evaluating complex peptide products, providing critical insights that have been invaluable to our development process. What truly sets ProImmune apart is their exceptional professionalism and commitment to supporting regulatory timelines. Their rigorous approach and high-quality services directly contributed to our ability to file peptide products with regulators efficiently. Working with ProImmune has been a consistently positive experience – their scientific excellence, combined with their understanding of regulatory requirements, makes them an ideal partner for any organization developing complex peptide therapeutics.“

Kanthikiran VS Varanasi (Galenicum, India)
“Working with ProImmune under demanding project timelines has been an exceptionally smooth experience. Their team consistently demonstrated remarkable agility and responsiveness, delivering high-quality immunogenicity risk assessment data without compromising on scientific rigor. When faced with tight internal deadlines and high-pressure milestones, ProImmune’s proactive execution and clear communication enabled us to stay on schedule. They have proven to be a highly reliable partner for time-sensitive, critical development programs.“